2. Search Result
Search Result
Results for "

HPV-16

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

10

Peptides

13

Recombinant Proteins

2

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-136465
    A2ti-1
    4 Publications Verification

    		 Annexin A Virus Protease HPV Infection
    A2ti-1 is a selective and high-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 24 μM . A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-1 prevents human papillomavirus type 16 (HPV16) infection .
    A2ti-1
  • HY-114698
    Retro-2 cycl
    1 Publications Verification

    RN 1-001

    		 Virus Protease Arenavirus HPV Infection
    Retro-2 cycl (RN 1-001) is a retrograde transport inhibitor with antiviral activity. Retro-2 cycl (RN 1-001) inhibits JCPyV and HPV16 pseudoviruses, with an IC50 of 54 μM and 160 μM respectively .
    Retro-2 cycl
  • HY-P1907
    Human Papillomavirus (HPV) E7 protein (49-57)

    		HPV Cancer
    Human Papillomavirus (HPV) E7 protein (49-57) is a cytotoxic T lymphocyte (CTL) epitope peptide derived from HPV16 E7 protein (sequence: RAHYNIVTF). Human Papillomavirus (HPV) E7 protein (49-57) induces E749-57-specific CTL responses. Human Papillomavirus (HPV) E7 protein (49-57) can be used for the research of cervical cancer .
    Human Papillomavirus (HPV) E7 protein (49-57)
  • HY-P11303
    PADRE peptide

    		CD74 MHC Neurological Disease Cancer
    PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4 + T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8 + T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer .
    PADRE peptide
  • HY-P1778A
    HPV16 E7 (86-93) TFA

    		HPV Infection
    HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .
    HPV16 E7 (86-93) TFA
  • HY-136466
    A2ti-2
    2 Publications Verification

    		 Annexin A Virus Protease HPV Infection
    A2ti-2 is a selective and low-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 230 μM . A2ti-2 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-2 prevents human papillomavirus type 16 (HPV16) infection .
    A2ti-2
  • HY-119098
    GSK983

    		EBV HPV Infection
    GSK983 is a broad-spectrum antiviral agent. GSK983 inhibits the replication of adenovirus-5 (Ad-5) and polyoma virus SV40. GSK983 inhibits the growth of cell lines immortalized by EBV, HTLV1, HPV. GSK983 induces the expression of interferon-stimulated genes .
    GSK983
  • HY-P5407
    HD5

    		SARS-CoV Angiotensin-converting Enzyme (ACE) Infection Cancer
    HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer .
    HD5
  • HY-163901
    E6-272

    		HPV Apoptosis Infection Cancer
    E6-272 is a human papillomavirus 16 (HPV 16) inhibitor. E6-272 induces Apoptosis. E6-272 inhibits the proliferation of HPV-positive cells. E6-272 can be used in the research of cervical cancer .
    E6-272
  • HY-P1778
    HPV16 E7 (86-93)

    		HPV Infection
    HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .
    HPV16 E7 (86-93)
  • HY-P5694
    Human α-defensin 5

    		HPV Parasite Infection
    Human α-defensin 5 is an antiviral peptide. Human α-defensin 5 blocks infection of non-enveloped viruses, including AdV, HPV, and polyomaviruses (IC50: 0.6-1.25 μM for HPV16). Human α-defensin 5 can bind to the viral capsid and blocks escape of the virus from the endosome. Human α-defensin 5 increases HIV binding to the cell surface. Human α-defensin 5 also has parasiticidal activity .
    Human α-defensin 5
  • HY-P1881
    HPV16-E711-20 epitope

    		HPV Cancer
    HPV16-E711-20 epitope is a well-known HLA-A *0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .
    HPV16-E711-20 epitope
  • HY-P10428
    E6AP-mimicking peptide

    		HPV Infection
    E6AP-mimicking peptide (compound 13) is a high-affinity, selective, irreversible and potent peptide-based covalent HPV16 E6 inhibitor targeting the 16E6 oncoprotein using a cysteine-reactive acrylamide warhead. E6AP-mimicking peptide has a Ki of 17 nM. E6AP-mimicking peptide targets all residues appearing in the binding pocket of E6 to disrupt the binding interface of 16E6 and E6AP. E6AP-mimicking peptide selectively binds and crosslinks to MBP-16E6 in PBS or a protein mixture .
    E6AP-mimicking peptide
  • HY-156584
    ODE-Bn-PMEG

    		Endogenous Metabolite Infection
    ODE-Bn-PMEG is an antiviral compound with strong inhibitory activity against HPV-11, -16, and -18. ODE-Bn-PMEG effectively reduced transient amplification of viral DNA in transfected cells at concentrations well below its cytotoxic levels. ODE-Bn-PMEG showed increased uptake in human foreskin fibroblasts and was able to be efficiently converted to the active antiviral metabolite PMEG diphosphate in vitro. The P-chiral enantiomer of ODE-Bn-PMEG showed comparable antiviral activity, indicating its potential application against multiple HPV types. ODE-Bn-PMEG is a promising candidate for local inhibition of HPV-16, HPV-18, and other high-risk types .
    ODE-Bn-PMEG
  • HY-P5407A
    HD5 TFA

    		SARS-CoV Angiotensin-converting Enzyme (ACE) Infection Cancer
    HD5 TFA is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 TFA binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 TFA can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer .
    HD5 TFA
  • HY-183322
    Antiviral agent 83

    		HPV Infection
    Antiviral agent 83 is a boronic acid-modified Neocryptolepine (HY-E70250) derivative and is an anti-HPV agent. Antiviral agent 83 bind to the viral capsid protein and/or envelope protein, inducing conformational changes that effectively obstruct the interaction between the virus and host cell receptors. Antiviral agent 83 exhibits inhibitory activity against multiple high-risk HPV strains. Antiviral agent 83 inhibits HPV infection in vitro and in vaginal tract in vivo .
    Antiviral agent 83

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: